Jingwei is a Senior Associate at F-Prime, where he focuses on early-stage investments in digital assets. Prior to F-Prime, he invested in fintech with a particular focus on capital markets and investment management platforms. He previously worked at BCG on strategy and digital transformation projects. He began his career at the Bank of England, conducting macroprudential analysis and working on new bank authorisations.
Jingwei holds an MSc in Finance from Imperial College London. His interest in crypto began in 2017, when he helped raise $20 million via an ICO for a blockchain-based digital bank.
Natasha Rodgers is an Associate in F-Prime’s London team, working across the life sciences sub-sectors including therapeutics and medical technology. Prior to joining F-Prime, Natasha was an associate consultant at Bain & Company. She also worked as a junior doctor in Edinburgh and Oxford with a particular focus area in Intensive Care. Natasha holds an MB BChir from Cambridge University and an A.B. in Molecular and Cellular Biology from Harvard University.
Bobby Gaspar is a Venture Partner with F-Prime based in London. Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) gene therapy technology—including some of the first studies in patients with severe primary immune deficiencies—bringing it from some of the first studies in patients into late-stage clinical trials. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other severe genetic conditions through targeted disease education, early diagnosis and comprehensive newborn screening.
Bobby was named to the inaugural TIME100 Health list in 2024, recognizing him as one of the world’s most influential individuals impacting human health. In addition to his role at Orchard, Bobby also serves as the chair of the board of directors at Eligo Biosciences, a privately-held biotech company expanding the scope of genetic medicines through gene-editing of the microbiome. He is also a venture partner at F-Prime, a global venture creation and investment firm with $4.5 billion under management.
Bobby is an honorary professor of pediatrics and immunology at the University College London (UCL) Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Great Ormond Street Institute of Child Health.
Anastasiya is a Senior Associate with F-Prime’s London team, focusing on healthcare investments. Prior to joining F-Prime in 2022, Ana was an Engagement Manager at McKinsey in London specializing in Pharmaceuticals & Medical Products. She had also worked as a Strategy Consultant at Advancy.
Ana holds a Ph.D. in Stem Cell Biology and Medicine from the University of Cambridge (UK), a MSc in Molecular and Cell Biology from École normale supérieure (Paris, France) and a BSc in Biology from Ivan Franko National University of Lviv (Ukraine).
Garth Rapeport joined F-Prime in 2021 as an Entrepreneur-in-Residence on the healthcare team. Garth is visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London. He was previously co-founder and CEO of Pulmocide and Respivert Ltd. which were drug discovery companies focused on the identification of novel disease modifying treatments for severe asthma and new generation inhaled antiviral and antifungal agents.
Garth is a medical graduate who undertook post-graduate training at the Universities of Glasgow and Oxford. After working at Pfizer Research in the UK he moved to GSK where he was SVP of Drug Discovery in the Respiratory area in which he led the discovery and early development new inhaled therapies for asthma and COPD.
Martin is Principal based in the Boston office. Martin’s primary area of interest is in biotechnology investments in a range of therapeutic areas including oncology, cardiovascular, renal and metabolic diseases. Martin joined F-Prime’s London office in 2019, where he has worked on several biotechnology company creation efforts and investments in Europe, including ARTBIO, CHARM Therapeutics and Tenpoint Therapeutics.
Prior to joining F-Prime, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication. Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell, Nature and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.
Rosy Howell joined the F-Prime team in March 2017. She is Executive Assistant to Alex Pasteur and Nihal Sinha. Previously, she worked at Henry Milner & Co. as Office Manager and Executive Assistant to Henry Milner. Rosy received her BA in Philosophy and English from the University of Southampton.
Nihal Sinha is a Partner at F-Prime based in the London office and focuses primarily on biotech and life sciences in Europe and the US.
At F-Prime, Nihal was a member of the founding team of Orchard Therapeutics and an investor in Ensoma, Curie Bio, Charm Therapeutics, Aviado Bio, and T-Therapeutics. Prior to joining F-Prime in 2013, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals.
Nihal holds a MB BChir with distinction from the University of Cambridge and is a Member of the Royal College of Physicians.
Alex Pasteur joined F-Prime in 2012 and is a Partner based in London. Alex focuses on investments in therapeutics and the convergence of life sciences with data science. Alex serves on the boards of ARTBIO, Nodthera, Tenpoint Therapeutics, Pulmocide, Peptone, Oviva, Genomics Ltd, Owkin and Shift Bioscience. He is an observer on the board of Castor.
Alex previously served on the boards of Orchard Therapeutics (acquired by Kyowa Kirin), Acacia Pharma (acquired by Eagle Pharmaceuticals), Arvelle Therapeutics (acquired by Angelini Pharma) and as observer for Adaptimmune Therapeutics (NASDAQ: ADAP).
Alex has worked in healthcare investing since 2001. Prior to joining F-Prime, Alex worked at MVM Life Science Partners LLP in the USA and Europe. Alex holds a M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.